当前位置: X-MOL 学术J. Vet. Pharmacol. Thera. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pharmacokinetics and bioavailability of oral firocoxib in adult, mixed-breed goats.
Journal of Veterinary Pharmacology and Therapeutics ( IF 1.3 ) Pub Date : 2019-08-21 , DOI: 10.1111/jvp.12795
Amy K Stuart 1 , Butch KuKanich 2 , Luciano S Caixeta 1, 3 , Johann F Coetzee 2 , Emily A Barrell 1, 3
Affiliation  

Pharmacokinetic (PK) studies of oral firocoxib in large animal species have been limited to horses, preruminating calves, and adult camels. The aim of this study was to describe pharmacokinetics and bioavailability of firocoxib in adult goats. Ten healthy adult goats were administered 0.5 mg/kg firocoxib intravenously (i.v.) and per os (p.o.) in a randomized, crossover study. Plasma firocoxib concentrations were measured over a 96-hr period for each treatment using HPLC and mass spectrometry, and PK analysis was performed. The p.o. formulation reached mean peak plasma concentration of 139 ng/ml (range: 87-196 ng/ml) in 0.77 hr (0.25-2.00 hr), and half-life was 21.51 hr (10.21-48.32 hr). Mean bioavailability was 71% (51%-82%), indicative of adequate gastrointestinal absorption of firocoxib. There were no negative effects observed in any animal, and all blood work values remained within or very near reference range at the study's conclusion. Results indicate that oral firocoxib is well-absorbed and rapidly reaches peak plasma concentrations, although the concentration also decreased quickly prior to the terminal phase. The prolonged half-life may suggest tissue accumulation and higher plasma concentrations over time, depending on dosing schedule. Further studies to determine tissue residue depletion, pharmacodynamics, and therapeutic concentrations of firocoxib in goats are necessary.

中文翻译:

成年混种山羊口服赛洛昔布的药代动力学和生物利用度。

口服氟罗昔布在大型动物物种中的药代动力学(PK)研究仅限于马,小牛和成年骆驼。这项研究的目的是描述辉罗昔布在成年山羊中的药代动力学和生物利用度。在随机,交叉研究中,对十只健康的成年山羊分别静脉内(iv)和口服(口服)给予0.5 mg / kg吡罗昔布。使用HPLC和质谱法在每次治疗的96小时内测量血浆fireocoxib的浓度,并进行PK分析。po制剂在0.77小时(0.25-2.00小时)中达到139ng / ml(范围:87-196ng / ml)的平均峰值血浆浓度,半衰期为21.51小时(10.21-48.32小时)。平均生物利用度为71%(51%-82%),表明赛洛昔布有足够的胃肠道吸收。在任何动物中都没有观察到负面影响,研究结束时,所有血液工作值均保持在参考范围内或非常接近参考范围。结果表明,口服吡罗昔布被吸收良好,并迅速达到峰值血浆浓度,尽管该浓度在终末期之前也迅速降低。延长的半衰期可能表明组织随时间推移而积累,血浆浓度更高,具体取决于给药时间表。进一步研究以确定山羊体内非洛昔布的组织残留消耗,药效学和治疗浓度是必要的。延长的半衰期可能表明组织随时间推移而积累,血浆浓度更高,具体取决于给药时间表。进一步研究以确定山羊体内非洛昔布的组织残留消耗,药效学和治疗浓度是必要的。延长的半衰期可能表明组织随时间推移而积累,血浆浓度更高,具体取决于给药时间表。进一步研究以确定山羊体内非洛昔布的组织残留消耗,药效学和治疗浓度是必要的。
更新日期:2019-11-01
down
wechat
bug